J
Joachim von Pawel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 144
Citations - 27028
Joachim von Pawel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 52, co-authored 142 publications receiving 25012 citations.
Papers
More filters
Journal ArticleDOI
Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak,Dongsheng Tu,Lesley Seymour,Gary M. Clark,Aleksandra Trajkovic,Mauro Zukin,Joseph Ayoub,Sergio Lago,Ronaldo A. Ribeiro,Alexandra Gerogianni,Arnold Cyjon,Jonathan Noble,Francis Laberge,Raymond T. T. Chan,David Fenton,Joachim von Pawel,Martin Reck,Frances A. Shepherd +17 more
TL;DR: Eerrlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
Journal ArticleDOI
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
Ramaswamy Govindan,Aleksandra Szczesna,Myung-Ju Ahn,Claus Peter Schneider,Pablo González Mella,Fabrice Barlesi,Baohui Han,Doina Elena Ganea,Joachim von Pawel,Vladimir Vladimirov,Natalia Fadeeva,Ki Hyeong Lee,Takayasu Kurata,Li Zhang,Tomohide Tamura,Pieter E. Postmus,Jacek Jassem,Kenneth J. O'Byrne,Justin Kopit,Mingshun Li,Marina Tschaika,Martin Reck +21 more
TL;DR: The addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone in patients with advanced squamous NSCLC and the safety profile was consistent with that observed in previous lung and melanoma studies.
Journal ArticleDOI
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara,Jean-Yves Douillard,Kazuhiko Nakagawa,Joachim von Pawel,Mark J. McKeage,I. Albert,György Losonczy,Martin Reck,Dae Seog Heo,Xiaolin Fan,Abderrahim Fandi,Giorgio V. Scagliotti +11 more
TL;DR: The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
Journal ArticleDOI
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel,Robert M. Jotte,David R. Spigel,Mary O'Brien,Mark A. Socinski,J. Mezger,Martin Steins,Léon Bosquee,Jeffrey A. Bubis,Kristiaan Nackaerts,Jose Manuel Trigo,Philip Clingan,W. Schütte,Paul Lorigan,Martin Reck,Manuel Domine,Frances A. Shepherd,Shaoyi Li,Markus F. Renschler +18 more
TL;DR: AmRubicin did not improve survival when compared with topotecan in the second-line treatment of patients with SCLC, although an improvement in OS was noted in patients with refractory disease treated with amrubicin.
Journal ArticleDOI
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Joachim von Pawel,Silvia Novello,Rodryg Ramlau,Adolfo Favaretto,Fabrice Barlesi,Wallace Akerley,Sergey Orlov,Armando Santoro,David R. Spigel,Vera Hirsh,Frances A. Shepherd,Lecia V. Sequist,Alan Sandler,Jeffrey S. Ross,Qiang Wang,Reinhard von Roemeling,Dale Shuster,Brian Schwartz +18 more
TL;DR: E + T was well tolerated and increased PFS but did not improve OS in the overall nonsquamous NSCLC population, and exploratory subgroup analyses suggested OS improvement in patients with high MET expression.